Sharat Singh

6.0k total citations
120 papers, 3.9k citations indexed

About

Sharat Singh is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Sharat Singh has authored 120 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Genetics, 44 papers in Epidemiology and 27 papers in Immunology. Recurrent topics in Sharat Singh's work include Inflammatory Bowel Disease (52 papers), Microscopic Colitis (42 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). Sharat Singh is often cited by papers focused on Inflammatory Bowel Disease (52 papers), Microscopic Colitis (42 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). Sharat Singh collaborates with scholars based in United States, Belgium and India. Sharat Singh's co-authors include Scott Hauenstein, Séverine Vermeire, Linda Ohrmund, Ann Gils, Niels Vande Casteele, Paul Rutgeerts, Goverdhan Mehta, Steven Lockton, Fred Princen and Edwin F. Ullman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Journal of Clinical Oncology.

In The Last Decade

Sharat Singh

112 papers receiving 3.8k citations

Peers

Sharat Singh
Penelope A. Morel United States
Shunsuke Kagawa Japan
Thomas H. Tötterman Sweden
François Martin France
Mark A. Goldsmith United States
Sonia Quaratino United Kingdom
Leonor David Portugal
Kevin F. Staveley-O’Carroll United States
Marco Novelli United Kingdom
P. Schlag Germany
Penelope A. Morel United States
Sharat Singh
Citations per year, relative to Sharat Singh Sharat Singh (= 1×) peers Penelope A. Morel

Countries citing papers authored by Sharat Singh

Since Specialization
Citations

This map shows the geographic impact of Sharat Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharat Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharat Singh more than expected).

Fields of papers citing papers by Sharat Singh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharat Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharat Singh. The network helps show where Sharat Singh may publish in the future.

Co-authorship network of co-authors of Sharat Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Sharat Singh. A scholar is included among the top collaborators of Sharat Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharat Singh. Sharat Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hanžel, Jurij, Bram Verstockt, Sharat Singh, et al.. (2025). Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profiles. Journal of Crohn s and Colitis. 19(1). 1 indexed citations
2.
Döll, W, Erik P. Sandefer, Richard C. Page, et al.. (2024). Su1778 RESULTS OF HUMAN DEVICE FUNCTION STUDIES FOR THE NAVICAP™ TARGETED ORAL DELIVERY PLATFORM IN HEALTHY VOLUNTEERS AND PATIENTS WITH UC. Gastroenterology. 166(5). S–809. 1 indexed citations
3.
Quintana, Nelson, et al.. (2023). POTENTIAL EFFECTS OF FOOD ON A NOVEL DRUG DELIVERY SYSTEM (DDS) TO DELIVER A THERAPEUTIC COMPOUND IN THE COLON. Inflammatory Bowel Diseases. 29(Supplement_1). S11–S11. 1 indexed citations
4.
5.
Martin, Kathleen A., Erik P. Sandefer, Richard C. Page, et al.. (2022). S1061 A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System (DDS) Device in Patients With Active Ulcerative Colitis (UC) in a Fasted State. The American Journal of Gastroenterology. 117(10S). e768–e769. 1 indexed citations
6.
Sandefer, Erik P., et al.. (2022). S1058 A Scintigraphic Study to Evaluate the Safety, Tolerability, and Functions of a Drug Delivery System (DDS) Device in Healthy Subjects in Fasted State. The American Journal of Gastroenterology. 117(10S). e766–e767. 1 indexed citations
7.
Matray, Tracy J., et al.. (2020). A novel class of polymeric fluorescent dyes assembled using a DNA synthesizer. PLoS ONE. 15(12). e0243218–e0243218. 3 indexed citations
8.
Calderón‐Gómez, Elisabeth, Rut Mora‐Buch, Isabella Dotti, et al.. (2016). Commensal-Specific CD4+ Cells From Patients With Crohn’s Disease Have a T-Helper 17 Inflammatory Profile. Gastroenterology. 151(3). 489–500.e3. 70 indexed citations
9.
Yarur, Andrés, Anjali Jain, Daniel A. Sussman, et al.. (2015). The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 65(2). 249–255. 178 indexed citations
10.
Billiet, Thomas, Konstantinos Papamichael, Magali de Bruyn, et al.. (2015). A Matrix-based Model Predicts Primary Response to Infliximab in Crohn’s Disease. Journal of Crohn s and Colitis. 9(12). 1120–1126. 47 indexed citations
11.
Yarur, Andrés, Frank Czul, Daniel A. Sussman, et al.. (2015). Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy. Clinical Gastroenterology and Hepatology. 13(6). 1118–1124.e3. 121 indexed citations
12.
Casteele, Niels Vande, Reena Khanna, Barrett G. Levesque, et al.. (2014). The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 64(10). 1539–1545. 224 indexed citations
13.
Lee, Jeeyun, Anjali Jain, Phillip Kim, et al.. (2014). Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status. PLoS ONE. 9(8). e103551–e103551. 18 indexed citations
14.
Yarur, Andrés, Katherine Drake, Scott Hauenstein, et al.. (2014). 788 Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy. Gastroenterology. 146(5). S–134. 3 indexed citations
15.
Plevy, Scott E., Mark S. Silverberg, S. Lockton, et al.. (2013). Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohnʼs Disease, and Ulcerative Colitis Patients. Inflammatory Bowel Diseases. 19(6). 1139–1148. 97 indexed citations
16.
Casteele, Niels Vande, Ann Gils, Sharat Singh, et al.. (2013). Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient. The American Journal of Gastroenterology. 108(6). 962–971. 280 indexed citations
17.
Serra, Violeta, Maurizio Scaltriti, Ludmila Prudkin, et al.. (2011). PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 30(22). 2547–2557. 433 indexed citations
18.
Mehta, Goverdhan & Sharat Singh. (2006). Total Synthesis of (±)‐Merrilactone A. Angewandte Chemie International Edition. 45(6). 953–955. 72 indexed citations
19.
Roux, Pascale, Stéphane Soubigou, Sylvain Ricard, et al.. (2004). Direct Measurement of Multiple mRNAs in Nerve Growth Factor-Induced PC12 Cells Using Electrophoretic Tags to Monitor Biomarkers of Neuronal Differentiation in 96-Well Format. Assay and Drug Development Technologies. 2(6). 637–646. 1 indexed citations
20.
Singh, Sharat, M.M. Bhadbhade, K. Venkatesan, & V. Ramamurthy. (1982). Strain assisted .alpha.-cleavage reactions of thio ketones: diphenylcyclopropenethione. The Journal of Organic Chemistry. 47(18). 3550–3553. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Penelope A. Morel Breakdown of academic impact, for papers by Shunsuke Kagawa Breakdown of academic impact, for papers by Thomas H. Tötterman Breakdown of academic impact, for papers by François Martin Breakdown of academic impact, for papers by Mark A. Goldsmith Breakdown of academic impact, for papers by Sonia Quaratino Breakdown of academic impact, for papers by Leonor David Breakdown of academic impact, for papers by Kevin F. Staveley-O’Carroll Breakdown of academic impact, for papers by Marco Novelli Breakdown of academic impact, for papers by P. Schlag
Rankless by CCL
2026